Matinas BioPharma Holdings, Inc. (MTNB) Stock Price

MTNBStock

$0.20−90.77%52W

Market Cap$2.90M

P/E—

PEG Ratio—

Div yield—

Beta2.09

MTNB Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-79.55%

Price vs S&P 500 (4W)-35.99%

VGM Score48.53

Book Value / Share (Quarterly)$0.47

P/TBV (Annual)1.46x

Cash Flow / Share (Quarterly)$-1.03

Price vs S&P 500 (YTD)-78.43%

Net Profit Margin (TTM)-479.27%

EPS (TTM)$-1.62

10-Day Avg Trading Volume2.01M

EPS Excl Extra (TTM)$-1.62

EPS (Annual)$-4.98

ROI (Annual)-318.80%

Net Profit Margin (5Y Avg)-21226.03%

Cash / Share (Quarterly)$0.37

ROA (Last FY)-191.84%

EBITD / Share (TTM)$-0.89

ROE (5Y Avg)-115.12%

Operating Margin (TTM)-483.12%

Cash Flow / Share (Annual)$-1.09

P/B Ratio1.06x

P/B Ratio (Quarterly)1.06x

Net Income / Employee (Annual)$-12,125,500

EV / Revenue (TTM)0.19x

Net Interest Coverage (TTM)-459.25x

ROA (TTM)-92.02%

EPS Incl Extra (Annual)$-4.98

Current Ratio (Annual)2.79x

Quick Ratio (Quarterly)1.15x

3-Month Avg Trading Volume3.89M

52-Week Price Return-90.77%

Revenue / Employee (TTM)$0

Tangible BV / Share (Quarterly)$0.12

P/S Ratio (Annual)2.92x

Asset Turnover (Annual)0.04x

52-Week High$2.24

Operating Margin (5Y Avg)-21513.86%

EPS Excl Extra (Annual)$-4.98

Tangible BV CAGR (5Y)-46.87%

26-Week Price Return-68.31%

Quick Ratio (Annual)2.77x

13-Week Price Return-70.67%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)1.32x

Enterprise Value$813,100

Asset Turnover (TTM)0.09x

Book Value / Share Growth (5Y)18.81%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-2093.25%

Cash / Share (Annual)$0.62

3-Month Return Std Dev159.16%

Net Income / Employee (TTM)$-4,344,500

ROE (Last FY)-319.51%

EPS Basic Excl Extra (Annual)$-4.98

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.62

ROI (TTM)-137.17%

P/S Ratio (TTM)0.75x

Pretax Margin (5Y Avg)-21226.03%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$0.40

Price vs S&P 500 (52W)-109.09%

Year-to-Date Return-66.47%

5-Day Price Return-3.53%

EPS Normalized (Annual)$-4.98

ROA (5Y Avg)-79.94%

Net Profit Margin (Annual)-2093.25%

Month-to-Date Return-33.12%

Cash Flow / Share (TTM)$-0.10

EBITD / Share (Annual)$-4.98

Operating Margin (Annual)-2124.27%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-114.93%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.62

P/TBV (Quarterly)4.20x

P/B Ratio (Annual)0.78x

Pretax Margin (TTM)-479.27%

Book Value / Share (Annual)$0.75

Price vs S&P 500 (13W)-73.46%

Beta2.09x

Revenue / Share (TTM)$0.00

ROE (TTM)-137.45%

52-Week Low$0.18

vGradeA

mGradeF

vgmGradeC

MTNB Earnings Surprise History

Q2 24-0.02est. -1.00

Q3 24-0.85est. -1.05

Q4 24-0.81est. -0.78

MTNB Analyst Recommendations

Jun 2025

Jul 2025

Aug 2025

Oct 2025

2.29

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
MTNBMatinas BioPharma Holdings, Inc.	A	—	F	$0.20
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Matinas BioPharma Holdings, Inc.

Matinas BioPharma is a clinical-stage biopharmaceutical company developing novel pharmaceutical treatments. The company's pipeline includes MAT2203, MAT2501, and other therapeutic candidates. The company focuses on identifying and advancing innovative drug candidates through clinical development.